Royalty Report: Drugs, Personal Care Products, Disease – Collection: 26699


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Personal Care Products
  • Disease
  • Osteoarthritis
  • Proteins
  • Therapeutic
  • Biotechnology
  • Pharmaceuticals
  • Hair loss
  • Psoriasis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26699

License Grant
Licensor hereby grants to the Company and the Company accepts, subject to the terms and conditions of this Agreement, an exclusive worldwide sublicense to the PTH Patent Rights, Know-how and Improvements for all uses, and to make, have made, use, lease and/or sell the Licensed Products, to the full end of the term for which the PTH Patent Rights are granted, unless sooner terminated as hereinafter provided.
License Property
PTH Patent Rights shall mean all claims for the clinical uses of PTH 1-34 contained in any and U.S. and foreign patents and patent applications set forth on Schedule 1.3.
Field of Use
The rights granted apply to PTH 1-34 which relates to the regulation of cell differentiation and proliferation for treatment of skin disorders.

IPSCIO Record ID: 256310

License Grant
The Parties previously entered into the Agreement to provide for the license grant of certain Licensed Technology to discover, develop, make, have made, market, sell and import certain Licensed Products throughout the world under the Licensees Patent Rights and Licensees Know-How.

With this amendment, Licensor consents and agrees that Licensee may enter into one or more agreements with a designated Third Party providing for the development, manufacturing, marketing or sale of 1-34 PTH into a drug product in the Field in finished pharmaceutical form in an oral formulation containing or incorporating 1-34 PTH, alone or in combination with a peptide or a small molecule that is not proprietary to Licensor, and which such oral formulation of 1-34 PTH product incorporates Licensee Know-How or is covered by Licensee Patent Rights, a 1-34 PTH Product.

With this amendment, Licensor grants back to Licensee, but only to the extent necessary to effectuate the specific Third Party Agreement, an exclusive license, even as to Licensor, under the Licensed Technology that relates solely to the manufacturing of 1-34 PTH API for use solely in a 1-34 PTH Product for Licensee to make and sell to Third Party, and for Third Party as Licensee’s licensee to subsequently sell, have sold, make, have made and import 1-34 PTH API for use solely in a 1-34 PTH Product in the Territory in the Field. For the avoidance of doubt, the foregoing license back to Licensee shall only apply to Licensed Technology that is solely related to the manufacturing of 1-34 PTH API for use solely in a 1-34 PTH Product and not any other aspects of Licensed Technology such as, but not limited to, Licensed Technology as to the oral delivery method or amidation technology relating to 1-34 PTH API or a 1-34 PTH Product, and Licensor retains all other rights to the Licensed Technology granted to Licensor under the Agreement.

License Property
1-34 PTH means all formulations of PTH 1-34OH including, but not limited to fusion proteins, muteins and chemical modifications of any or all of the aforementioned PTH 1-34OH. For the avoidance of doubt, 1-34 PTH shall not include any other formulations of PTH 1-34 or any other formulations of PTH.
Field of Use
This amendment further defines that the product in the Field may be in the finished pharmaceutical form in an oral formulation.  The original agreement defines the Field as the use of the Licensed Product for the prophylactic and/or therapeutic treatment of human diseases including, but not limited to, osteoporosis.

IPSCIO Record ID: 5995

License Grant
Pursuant to this Agreement Licensee now has worldwide, exclusive License rights to the U.S. and foreign patents and patent applications for all topical uses of PTH(1-34) for the treatment of hyperproliferative skin disorders including psoriasis.
Field of Use
Field of use relates to the medical industry.

IPSCIO Record ID: 28991

License Grant
Licensor grants an exclusive license for the Licensed Technology in the Field, including, without limitation, the patents and patent applications with the right to grant sublicenses, as well as the right of its sublicensees to grant further sublicenses, to make, have made, use, distribute and sell Licensed Products in the Field using the Licensed Technology covered by the Licensed Patent Rights throughout the Territory.
License Property
PTH technologies useful in the treatment of psoriasis and hair loss.

U.S. Patent No. 5,527,772, 5,840,690, 6,066,618

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.